Multinational clinical trials in oncology and post-trial benefits for host countries: where do we stand?

European Journal of Cancer

Volumn 42, Issue 16, 2006, Pages 2675-2677

  Mano, Max S ^a   Rosa, Daniela D ^a   Lago, Lissandra Dal ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Developing countries; Drug costs; Health economies; International research

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; PACLITAXEL; TRASTUZUMAB;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BREAST CANCER; CANCER RESEARCH; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; GOOD CLINICAL PRACTICE; HEALTH CARE ACCESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL DECISION MAKING; PATENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; RESEARCH ETHICS; TREATMENT INDICATION;

CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DEVELOPING COUNTRIES; ETHICS, RESEARCH; MULTICENTER STUDIES; MULTICENTER STUDIES AS TOPIC; NEOPLASMS; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC;

EID: 33750090720     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.02.028     Document Type: Article

References (11)

1. Schwartsmann G., Ratain M.J., Cragg G.M., et al. Anticancer drug discovery and development throughout the world. J Clin Oncol 20 suppl 18 (2002) 47S-59S
2. Hebert-Croteau N., Brisson J., Lemaire J., and Latreille J. The benefit of participating to clinical research. Breast Cancer Res Treat 91 3 (2005) 279-281
3. Du Bois A., Rochon J., Lamparter C., and Pfisterer J. AGO Organkommission OVAR PFisterer. Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Int J Gynecol Cancer 15 2 (2005) 183-191
4. Mano M. The burden of scientific progress: growing inequalities in the delivery of cancer care. Acta Oncol 45 1 (2006) 84-86
5. Demonty G. Treatment guidelines for adjuvant breast cancer are moving toward double standards: one for the rich and one for the poor. J Clin Oncol 23 36 (2005) 9436-9437
6. Tirelli U., de Castro G.J., and Awada A. Reimbursement of effective new anticancer agents: we should change the process to ensure wide access to patients. Lancet Oncol 7 1 (2006) 2-3
7. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 11 (2001) 783-792
8. Marty M., Cognetti F., Maraninchi D., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23 19 (2005) 4265-4274
9. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 16 (2005) 1659-1672
10. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC → T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC → TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. San Antonio Breast Cancer Symposium, 8-11 December 2005 (abstr 1).
11. National Bioethics Advisory Committee (NBAC). Ethical and policy issues in international research: clinical trials in developing countries. April 30, 2001. Available from: www.bioethics.gov.